Cobalt Files ANDA For AstraZeneca’s Crestor
This article was originally published in The Pink Sheet Daily
Executive Summary
Cobalt seeks to market generic rosuvastatin in 5, 10, 20 and 40 mg doses, firm says in an Oct. 30 letter to AstraZeneca.
You may also be interested in...
AstraZeneca Files Patent Infringement Suits Against Seven Generic Drugmakers Over Crestor
Nine companies in all have filed ANDAs with Paragraph IV certification against a Crestor patent, but two indicated they will not launch generic rosuvastatin prior to the patent’s expiry, AstraZeneca tells DAILY.
AstraZeneca Files Patent Infringement Suits Against Seven Generic Drugmakers Over Crestor
Nine companies in all have filed ANDAs with Paragraph IV certification against a Crestor patent, but two indicated they will not launch generic rosuvastatin prior to the patent’s expiry, AstraZeneca tells DAILY.
Abbott, AstraZeneca To Combine Next-Generation Fenofibrate With Crestor In Phase III
The companies are aiming to submit the lipid-regulating combination in 2009.